Are you a healthcare professional?
This page contains clinical information intended for licensed healthcare professionals. By continuing, you confirm that you are a qualified medical practitioner.
For referring physicians
You are the decision-maker for your patient. This page gives you what you need to stand behind a referral professionally.
"If I send my patient, can I stand behind it professionally?"
Eligibility criteria
Clear patient selection criteria, reviewed case by case — so you know before referral whether your patient fits the programme.
Product and target information
Target antigens (CD19/CD22 dual-target, BCMA), manufacturing chain and quality framework — shared in full detail.
CRS and ICANS protocols
Grading and management protocols for cytokine release syndrome and neurotoxicity, aligned with the treating centre.
Conditioning feasibility
Where clinically appropriate, the conditioning regimen can be administered in the patient's own country — shortening the stay in Türkiye.
Single point of contact
One coordinator for the entire pathway — from referral to data return. No call centres, no handovers.
Data you receive
When your patient returns, you receive structured follow-up data in a format you can use — continuing the care you started.
Clinical data package
Registered access gives you the full study data behind these programmes — published references, phase information and safety profiles — for your own evaluation.
Request the clinical data packageEvidence
36 publications behind these programmes
Clinical trials, case reports and preclinical studies supporting the Hillgene CD19/CD22, Hillgene BCMA and UniCar CAR-T therapy programmes — all with PubMed links.
Pipeline
Product Pipeline
First-in-class CAR-T products from our partner UniCar (Shanghai Ucardi Biomedical Technology) in registered clinical research phase.
U16 Injection (CD20 CAR-T)
Non-CD19 target lymphoma treatment. ASH 2024 data: 100% ORR, 68.75% CR rate in rituximab-refractory R/R B-NHL. Median PFS 14.5 months with good safety profile (no grade 4 CRS).
ssCART-19 Injection (CNS Leukemia)
Anti-CD19 CAR-T with IL-6 gene silencing for CNS B-cell ALL — a former CAR-T contraindication. FDA orphan drug designation, NMPA breakthrough therapy designation. Phase 1 showed complete symptom resolution with only grade 1 CRS.
U87 Injection (Fully Human CAR-T)
Fully human CAR-T product targeting solid tumors. Addresses immunogenicity limitations of murine-derived CAR-T. In registered clinical stage I.
Target Antigen-Expressing T Cells (TAET)
Novel strategy to enhance CAR-T efficacy in low tumor burden scenarios. CD19+ TAET cells restore CAR-T activation when residual tumor cells are below threshold, enabling deep clearance of MRD. ASH 2024 data presented.
Clinical data is shared with registered physicians only, with sources. This page does not publish efficacy figures.